Tempest Therapeutics Inc (TPST)

Jun 8, 2026, 8:00 AM EDT - 16 days ago

Tempest Therapeutics Proxy statement: Proxy filing

Jun 4, 2026, 4:37 PM EDT - 20 days ago

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

MD

May 29, 2026, 8:00 AM EDT - 26 days ago

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

May 29, 2026, 8:00 AM EDT - 26 days ago

Tempest Therapeutics Proxy statement: Proxy filing

May 14, 2026, 4:15 PM EDT - 5 weeks ago

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:00 PM EDT - 5 weeks ago

Tempest Therapeutics Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 5 weeks ago

Tempest Therapeutics Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 7 weeks ago

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026, 7:00 AM EDT - 7 weeks ago

Tempest Therapeutics Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

2026-04-22T12:30:21.000Z - 2 months ago

Tempest Therapeutics provides update on development of TPST-2003

Apr 22, 2026, 8:00 AM EDT - 2 months ago

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Apr 14, 2026, 8:00 AM EDT - 2 months ago

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Tempest Therapeutics Registration statement: Registration filing

2026-04-02T10:11:28.000Z - 2 months ago

Tempest Therapeutics files to sell 2.78M shares of common stock for holders

2026-03-30T22:05:33.000Z - 3 months ago

Tempest Therapeutics files to sell 8.27M shares of common stock for holders

Mar 30, 2026, 9:00 AM EDT - 3 months ago

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Mar 30, 2026, 8:30 AM EDT - 3 months ago

Tempest Therapeutics Annual report: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 3 months ago

Tempest Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 3 months ago

Tempest Therapeutics Registration statement: Registration filing

Mar 23, 2026, 8:00 AM EDT - 3 months ago

Tempest Therapeutics Announces Up To $6 Million Private Placement

2026-03-11T12:06:24.000Z - 3 months ago

Tempest, Cincinnati Children’s AGCTC partner for TPST-2003 registrational study

Mar 11, 2026, 8:00 AM EDT - 3 months ago

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

2026-02-25T13:24:11.000Z - 4 months ago

Tempest Therapeutics announces data from REDEEM-1 Phase 1/2a trial on TPST-2003

Feb 25, 2026, 7:59 AM EST - 4 months ago

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Feb 11, 2026, 6:59 AM EST - 4 months ago

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Feb 4, 2026, 4:47 PM EST - 5 months ago

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

2026-01-22T11:12:02.000Z - 5 months ago

Tempest Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Jan 20, 2026, 5:20 PM EST - 5 months ago

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Dec 31, 2025, 7:00 AM EST - 6 months ago

Tempest Therapeutics Proxy statement: Proxy Filing

2025-12-09T21:55:14.000Z - 7 months ago

Tempest Therapeutics files to sell 1.17M shares of common stock for holders

Dec 9, 2025, 7:00 AM EST - 7 months ago

Tempest Therapeutics Registration statement: Registration Filing

Dec 2, 2025, 7:00 AM EST - 7 months ago

Tempest Therapeutics Proxy statement: Proxy Filing

Nov 26, 2025, 4:05 PM EST - 7 months ago

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

2025-11-25T13:05:18.000Z - 7 months ago

Tempest Therapeutics prices 1.17M shares at $3.63 in registered direct offering

Nov 25, 2025, 8:00 AM EST - 7 months ago

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

2025-11-19T14:11:00.000Z - 7 months ago

Tempest announces acquisition of new dual-CAR T programs from Factor Bioscience

Nov 19, 2025, 9:00 AM EST - 7 months ago

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

BTX

Nov 19, 2025, 7:00 AM EST - 7 months ago

Tempest Therapeutics Proxy statement: Proxy Filing

Nov 5, 2025, 9:00 AM EST - 8 months ago

Tempest Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 9:00 AM EST - 8 months ago

Tempest Therapeutics Earnings release: Q3 2025

2025-11-05T13:36:56.000Z - 8 months ago

Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year

Nov 5, 2025, 8:30 AM EST - 8 months ago

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-08-11T20:55:19.000Z - 11 months ago

Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)

Aug 11, 2025, 4:12 PM EDT - 11 months ago

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:00 PM EDT - 11 months ago

Tempest Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 11 months ago

Tempest Therapeutics Earnings release: Q2 2025

2025-06-30T14:37:56.000Z - 1 year ago

Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

2025-06-11T12:20:36.000Z - 1 year ago

Tempest prices 739,000 shares at $6.25 in registered direct offering

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

2025-06-05T12:05:21.000Z - 1 year ago

Tempest Therapeutics receives ODD from EMA for amezalpat

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

2025-05-13T20:35:15.000Z - 1 year ago

Tempest Therapeutics reports Q1 EPS ($3.16), consensus ($3.29)

May 13, 2025, 4:28 PM EDT - 1 year ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q1 2025

Apr 28, 2025, 4:05 PM EDT - 1 year ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

2025-04-21T12:08:31.000Z - 1 year ago

Tempest Therapeutics announces FDA granted ODD to TPST-1495

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 9, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Tempest Therapeutics Slides: Corporate Presentation

Mar 27, 2025, 4:10 PM EDT - 1 year ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 13, 2025, 8:00 AM EDT - 1 year ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Feb 10, 2025, 8:00 AM EST - 1 year ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 7, 2025, 4:30 PM EST - 1 year ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 24, 2025, 7:00 AM EST - 1 year ago

Tempest Therapeutics Registration statement: Registration Filing

Jan 6, 2025, 8:00 AM EST - 1 year ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Dec 3, 2024, 9:00 AM EST - 1 year ago

Tempest Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 1 year ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 4:21 PM EST - 1 year ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing

Oct 10, 2024, 7:01 AM EDT - 1 year ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Sep 20, 2024, 4:30 PM EDT - 1 year ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Tempest Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 8, 2024, 4:56 PM EDT - 2 years ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q2 2024

Jul 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Registration statement: Registration Filing

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Transcript: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Slides: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Press release: Study Update

Jun 18, 2024, 6:22 PM EDT - 2 years ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 5, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: Jefferies Global Healthcare Conference

May 29, 2024, 2:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 9, 2024, 4:29 PM EDT - 2 years ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q1 2024

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing

Apr 9, 2024, 8:00 AM EDT - 2 years ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Mar 19, 2024, 4:25 PM EDT - 2 years ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q4 2023

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Annual report: Q4 2023

Mar 5, 2024, 4:30 PM EST - 2 years ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Mar 4, 2024, 9:10 AM EST - 2 years ago

Tempest Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Nov 28, 2023, 3:00 PM EST - 2 years ago

Tempest Therapeutics Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 2 years ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 5:00 AM EST - 2 years ago

Tempest Therapeutics Slides: Corporate Presentation

Nov 8, 2023, 5:17 PM EST - 2 years ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 4:00 PM EST - 2 years ago

Tempest Therapeutics Quarterly report: Q3 2023

Nov 8, 2023, 4:00 PM EST - 2 years ago

Tempest Therapeutics Earnings release: Q3 2023

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain